Artificial Intelligence for COVID-19 Drug Discovery and Vaccine Development

SARS-COV-2 has roused the scientific community with a call to action to combat the growing pandemic. At the time of this writing, there are yet no novel antiviral agents or approved vaccines available to be deployed as a frontline defense. Understanding the pathobiology of COVID-19 could aid scientists in their discovery of potent antivirals by elucidating unexplored viral pathways. One method to accomplish this is the leveraging of computational methods to discover new candidate drugs and vaccines in silico. In the last decade, machine learning-based models, trained on specific biomolecules, have offered both inexpensive and rapid implementation methods for the discovery of effective viral therapies. Given a target biomolecule, these models are capable of predicting inhibitor candidates in a structural-based manner. If enough data are presented to a model, they can aid the search for a drug or vaccine candidate by identifying patterns within the data. In this review, we focus on the recent advances of COVID-19 drug and vaccine development using artificial intelligence, and the potential of intelligent training for the discovery of COVID-19 therapeutics. To facilitate the applications of deep learning for SARS-COV-2, we highlight multiple molecular targets of COVID-19, inhibition of which may increase patient survival. Moreover, we present CoronaDB-AI, a dataset of compounds, peptides, and epitopes discovered either in silico or in vitro that can be potentially used for training models. The information and datasets provided in this review can be used to train deep learning-based models and accelerate the discovery of effective viral therapies y.